1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Europe SGLT2 Inhibitors Market Insights
4.1. Europe SGLT2 Inhibitors Market – Market Snapshot
4.2. Europe SGLT2 Inhibitors Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rising Geriatric Population in Europe Drives Market Growth
4.2.1.2. Increasing Government Initiatives Drive Market Outlook
4.2.2. Restraints and Challenges
4.2.2.1. Alternative Treatment Options
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Europe SGLT2 Inhibitors Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Europe SGLT2 Inhibitors Market, by Indication
5.1. Key Findings
5.2. Introduction
5.2.1. Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
5.3. Cardiovascular
5.3.1. Europe SGLT2 Inhibitors Market, by Cardiovascular, by Country, 2024-2032 (USD million)
5.4. Chronic Kidney Disease (CKD)
5.4.1. Europe SGLT2 Inhibitors Market, by Chronic Kidney Disease (CKD), by Country, 2024-2032 (USD million)
5.5. Type 2 Diabetes
5.5.1. Europe SGLT2 Inhibitors Market, by Type 2 Diabetes, by Country, 2024-2032 (USD million)
5.6. Others
5.6.1. Europe SGLT2 Inhibitors Market, by Others, by Country, 2024-2032 (USD million)
6. Europe SGLT2 Inhibitors Market, by Drug
6.1. Key Findings
6.2. Introduction
6.2.1. Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
6.3. Farxiga (Dapagliflozin)
6.3.1. Europe SGLT2 Inhibitors Market, by Farxiga (Dapagliflozin), by Country, 2024-2032 (USD million)
6.4. Inpefa (Sotagliflozin)
6.4.1. Europe SGLT2 Inhibitors Market, by Inpefa (Sotagliflozin), by Country, 2024-2032 (USD million)
6.5. Invokana (Canagliflozin)
6.5.1. Europe SGLT2 Inhibitors Market, by Invokana (Canagliflozin), by Country, 2024-2032 (USD million)
6.6. Jardiance (Empagliflozin)
6.6.1. Europe SGLT2 Inhibitors Market, by Jardiance (Empagliflozin), by Country, 2024-2032 (USD million)
6.7. Qtern (Dapagliflozin/Saxagliptin)
6.7.1. Europe SGLT2 Inhibitors Market, by Qtern (Dapagliflozin/Saxagliptin), by Country, 2024-2032 (USD million)
6.8. Other Europe SGLT2 Inhibitors
6.8.1. Europe SGLT2 Inhibitors Market, by Other Europe SGLT2 Inhibitors, by Country, 2024-2032 (USD million)
7. Europe SGLT2 Inhibitors Market, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.2.1. Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
7.3. Hospital Pharmacies
7.3.1. Europe SGLT2 Inhibitors Market, by Hospital Pharmacies, by Country, 2024-2032 (USD million)
7.4. Online Pharmacies
7.4.1. Europe SGLT2 Inhibitors Market, by Online Pharmacies, by Country, 2024-2032 (USD million)
7.5. Retail Pharmacies
7.5.1. Europe SGLT2 Inhibitors Market, by Retail Pharmacies, by Country, 2024-2032 (USD million)
8. Europe SGLT2 Inhibitors Market, by Country
8.1. Key Findings
8.2. Introduction
8.2.1. Europe SGLT2 Inhibitors Market Assessment, By Country, 2024-2032 (USD million)
8.3. Europe SGLT2 Inhibitors Market
8.3.1. Europe: Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
8.3.2. Europe: Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
8.3.3. Europe: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
8.3.4. Europe SGLT2 Inhibitors Market – UK
8.3.4.1. UK: Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
8.3.4.2. UK: Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
8.3.4.3. UK: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
8.3.5. Europe SGLT2 Inhibitors Market – France
8.3.5.1. France: Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
8.3.5.2. France: Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
8.3.5.3. France: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
8.3.6. Europe SGLT2 Inhibitors Market – Germany
8.3.6.1. Germany: Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
8.3.6.2. Germany: Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
8.3.6.3. Germany: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
8.3.7. Europe SGLT2 Inhibitors Market – Italy
8.3.7.1. Italy: Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
8.3.7.2. Italy: Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
8.3.7.3. Italy: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
8.3.8. Europe SGLT2 Inhibitors Market – Spain
8.3.8.1. Spain: Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
8.3.8.2. Spain: Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
8.3.8.3. Spain: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
8.3.9. Europe SGLT2 Inhibitors Market – Netherlands
8.3.9.1. Netherlands: Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
8.3.9.2. Netherlands: Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
8.3.9.3. Netherlands: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
8.3.10. Europe SGLT2 Inhibitors Market – Russia
8.3.10.1. Russia: Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
8.3.10.2. Russia: Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
8.3.10.3. Russia: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
8.3.11. Europe SGLT2 Inhibitors Market – Rest of Europe
8.3.11.1. Rest of Europe: Europe SGLT2 Inhibitors Market, by Indication, 2024-2032 (USD million)
8.3.11.2. Rest of Europe: Europe SGLT2 Inhibitors Market, by Drug, 2024-2032 (USD million)
8.3.11.3. Rest of Europe: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2024-2032 (USD million)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. AstraZeneca
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Boehringer Ingelheim International GmbH
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Bristol-Myers Squibb Company
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Eli Lilly and Company
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Glenmark Pharmaceuticals Ltd.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Lexicon Pharmaceuticals, Inc.
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Merck & Co., Inc.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Novo Nordisk
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Sanofi
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. Pfizer Inc.
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
著作権 ©2022 無断複写・転載を禁じます
